Herein, aiming to improve the immunotherapeutic efficacy and to reduce the tumor recurrence after RFA therapy, we designed a type of multifunctional nanodrug (PFH-Ce6 liposome@O2 nanodroplets, abbreviated as PCL@O2) to enhance the thermal ablation effect of RFA and improve the anti-PD-1 therapy after iRFA by encapsulating chlorine 6 (Ce6) as the sonosensitizers and phase-shifted perfluorohexane (PFH) liquid droplets as O2 reservoir, into liposomes (Figure 1). This evidence concerns the gene PDCD1 and neoplasm.